These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21317177)

  • 21. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
    Paramsothy S; Kamm MA; Kaakoush NO; Walsh AJ; van den Bogaerde J; Samuel D; Leong RWL; Connor S; Ng W; Paramsothy R; Xuan W; Lin E; Mitchell HM; Borody TJ
    Lancet; 2017 Mar; 389(10075):1218-1228. PubMed ID: 28214091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
    Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G
    Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.
    Kato K; Mizuno S; Umesaki Y; Ishii Y; Sugitani M; Imaoka A; Otsuka M; Hasunuma O; Kurihara R; Iwasaki A; Arakawa Y
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1133-41. PubMed ID: 15569116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.
    Miehlke S; Madisch A; Bethke B; Morgner A; Kuhlisch E; Henker C; Vogel G; Andersen M; Meier E; Baretton G; Stolte M
    Gastroenterology; 2008 Nov; 135(5):1510-6. PubMed ID: 18926826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis.
    Langmead L; Feakins RM; Goldthorpe S; Holt H; Tsironi E; De Silva A; Jewell DP; Rampton DS
    Aliment Pharmacol Ther; 2004 Apr; 19(7):739-47. PubMed ID: 15043514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
    Vermeire S; Danese S; Sandborn WJ; Schreiber S; Hanauer S; D'Haens G; Nagy P; Thakur M; Bliss C; Cataldi F; Goetsch M; Gorelick KJ; Reinisch W
    J Crohns Colitis; 2024 May; 18(5):708-719. PubMed ID: 38096402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
    van Deventer SJ; Tami JA; Wedel MK
    Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
    Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
    Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
    Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
    Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study.
    Stremmel W; Braun A; Hanemann A; Ehehalt R; Autschbach F; Karner M
    J Clin Gastroenterol; 2010; 44(5):e101-7. PubMed ID: 20048683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial.
    Bossa F; Fiorella S; Caruso N; Accadia L; Napolitano G; Valvano MR; Andriulli A; Annese V
    Am J Gastroenterol; 2007 Mar; 102(3):601-8. PubMed ID: 17156148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.